Research Analysts’ Weekly Ratings Changes for Biomea Fusion (BMEA)

Several brokerages have updated their recommendations and price targets on shares of Biomea Fusion (NASDAQ: BMEA) in the last few weeks:

• 4/8/2026 – Biomea Fusion had its “buy” rating reaffirmed by D. Boral Capital. They now have a $12.00 price target on the stock.
• 3/28/2026 – Biomea Fusion was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/27/2026 – Biomea Fusion had its price target raised by Citigroup Inc. from $6.00 to $7.00. They now have a “buy” rating on the stock.
• 3/25/2026 – Biomea Fusion had its “buy” rating reaffirmed by D. Boral Capital. They now have a $12.00 price target on the stock.

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.